vs
Esperion Therapeutics, Inc.（ESPR）与OFG BANCORP（OFG）财务数据对比。点击上方公司名可切换其他公司
OFG BANCORP的季度营收约是Esperion Therapeutics, Inc.的1.1倍（$184.3M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 0.9%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 2.8%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
OFG Bancorp成立于1964年，总部位于波多黎各圣胡安，是东方银行的金融控股公司。公司通过东方银行、东方金融服务有限责任公司、东方保险有限责任公司等核心子公司，主要面向波多黎各和美属维尔京群岛市场，提供多元化的零售与商业银行、贷款、财富管理相关产品、服务及技术解决方案。
ESPR vs OFG — 直观对比
营收规模更大
OFG
是对方的1.1倍
$168.4M
营收增速更快
ESPR
高出142.8%
0.9%
两年增速更快
ESPR
近两年复合增速
2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $184.3M |
| 净利润 | — | $55.9M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 25.7% |
| 净利率 | — | 30.3% |
| 营收同比 | 143.7% | 0.9% |
| 净利润同比 | — | 11.0% |
| 每股收益（稀释后） | $0.32 | $1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPROFG
| Q4 25 | $168.4M | $184.3M | ||
| Q3 25 | $87.3M | $186.2M | ||
| Q2 25 | $82.4M | $182.4M | ||
| Q1 25 | $65.0M | $178.6M | ||
| Q4 24 | $69.1M | $182.7M | ||
| Q3 24 | $51.6M | $174.7M | ||
| Q2 24 | $73.8M | $179.8M | ||
| Q1 24 | $137.7M | $174.4M |
净利润ESPROFG
| Q4 25 | — | $55.9M | ||
| Q3 25 | $-31.3M | $51.8M | ||
| Q2 25 | $-12.7M | $51.8M | ||
| Q1 25 | $-40.5M | $45.6M | ||
| Q4 24 | — | $50.3M | ||
| Q3 24 | $-29.5M | $47.0M | ||
| Q2 24 | $-61.9M | $51.1M | ||
| Q1 24 | $61.0M | $49.7M |
营业利润率ESPROFG
| Q4 25 | 50.6% | 25.7% | ||
| Q3 25 | -11.4% | 33.0% | ||
| Q2 25 | 8.6% | 36.1% | ||
| Q1 25 | -34.0% | 33.3% | ||
| Q4 24 | -6.4% | 28.9% | ||
| Q3 24 | -31.0% | 35.4% | ||
| Q2 24 | 3.5% | 39.6% | ||
| Q1 24 | 52.5% | 38.9% |
净利率ESPROFG
| Q4 25 | — | 30.3% | ||
| Q3 25 | -35.9% | 27.8% | ||
| Q2 25 | -15.4% | 28.4% | ||
| Q1 25 | -62.2% | 25.5% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | -57.2% | 26.9% | ||
| Q2 24 | -83.9% | 28.4% | ||
| Q1 24 | 44.3% | 28.5% |
每股收益（稀释后）ESPROFG
| Q4 25 | $0.32 | $1.27 | ||
| Q3 25 | $-0.16 | $1.16 | ||
| Q2 25 | $-0.06 | $1.15 | ||
| Q1 25 | $-0.21 | $1.00 | ||
| Q4 24 | $-0.14 | $1.10 | ||
| Q3 24 | $-0.15 | $1.00 | ||
| Q2 24 | $-0.33 | $1.08 | ||
| Q1 24 | $0.34 | $1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $1.0B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $1.4B |
| 总资产 | $465.9M | $12.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPROFG
| Q4 25 | $167.9M | $1.0B | ||
| Q3 25 | $92.4M | $740.3M | ||
| Q2 25 | $86.1M | $851.8M | ||
| Q1 25 | $114.6M | $710.6M | ||
| Q4 24 | $144.8M | $591.1M | ||
| Q3 24 | $144.7M | $680.6M | ||
| Q2 24 | $189.3M | $740.4M | ||
| Q1 24 | $226.6M | $754.4M |
股东权益ESPROFG
| Q4 25 | $-302.0M | $1.4B | ||
| Q3 25 | $-451.4M | $1.4B | ||
| Q2 25 | $-433.5M | $1.3B | ||
| Q1 25 | $-426.2M | $1.3B | ||
| Q4 24 | $-388.7M | $1.3B | ||
| Q3 24 | $-370.2M | $1.3B | ||
| Q2 24 | $-344.2M | $1.2B | ||
| Q1 24 | $-294.3M | $1.2B |
总资产ESPROFG
| Q4 25 | $465.9M | $12.5B | ||
| Q3 25 | $364.0M | $12.2B | ||
| Q2 25 | $347.1M | $12.2B | ||
| Q1 25 | $324.0M | $11.7B | ||
| Q4 24 | $343.8M | $11.5B | ||
| Q3 24 | $314.1M | $11.5B | ||
| Q2 24 | $352.3M | $11.3B | ||
| Q1 24 | $373.1M | $11.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $217.7M |
| 自由现金流经营现金流 - 资本支出 | — | $199.3M |
| 自由现金流率自由现金流/营收 | — | 108.1% |
| 资本支出强度资本支出/营收 | 0.0% | 10.0% |
| 现金转化率经营现金流/净利润 | — | 3.90× |
| 过去12个月自由现金流最近4个季度 | — | $345.4M |
8季度趋势，按日历期对齐
经营现金流ESPROFG
| Q4 25 | $45.2M | $217.7M | ||
| Q3 25 | $-4.3M | $39.5M | ||
| Q2 25 | $-31.4M | $35.9M | ||
| Q1 25 | $-22.6M | $83.1M | ||
| Q4 24 | $-35.0M | $252.5M | ||
| Q3 24 | $-35.3M | $58.1M | ||
| Q2 24 | $-7.2M | $95.1M | ||
| Q1 24 | $53.8M | $61.0M |
自由现金流ESPROFG
| Q4 25 | — | $199.3M | ||
| Q3 25 | — | $35.5M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $78.7M | ||
| Q4 24 | — | $231.2M | ||
| Q3 24 | $-35.5M | $51.8M | ||
| Q2 24 | $-7.3M | $90.4M | ||
| Q1 24 | $53.8M | $54.8M |
自由现金流率ESPROFG
| Q4 25 | — | 108.1% | ||
| Q3 25 | — | 19.1% | ||
| Q2 25 | — | 17.4% | ||
| Q1 25 | — | 44.1% | ||
| Q4 24 | — | 126.5% | ||
| Q3 24 | -68.7% | 29.6% | ||
| Q2 24 | -9.9% | 50.3% | ||
| Q1 24 | 39.0% | 31.4% |
资本支出强度ESPROFG
| Q4 25 | 0.0% | 10.0% | ||
| Q3 25 | 0.0% | 2.1% | ||
| Q2 25 | 0.0% | 2.3% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | 0.0% | 11.7% | ||
| Q3 24 | 0.3% | 3.6% | ||
| Q2 24 | 0.1% | 2.6% | ||
| Q1 24 | 0.1% | 3.5% |
现金转化率ESPROFG
| Q4 25 | — | 3.90× | ||
| Q3 25 | — | 0.76× | ||
| Q2 25 | — | 0.69× | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 5.02× | ||
| Q3 24 | — | 1.24× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | 0.88× | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
OFG
暂无分部数据
